Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease.

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014 · see citing works

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies

Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · see citing works

Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial

Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986 · see citing works

The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein

Beisiegel†, U., Weber, W. T., Ihrke, G., Herz, J., & Stanley, K. K. (1989) · Nature · doi:10.1038/341162a0 · Cited by 680 · see citing works

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes

Fontbonne, A., Eschw�ge, E., Cambien, F., Richard, J. L., Ducimeti�re, P., Thibult, N., Warnet, J., Claude, J., & Rosselin, G. (1989) · Diabetologia · doi:10.1007/bf00265546 · Cited by 616 · see citing works

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · see citing works

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo

Ginsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424 · see citing works

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Wang, C. S., McConathy, W. J., Kloer, H. U., & Alaupovic, P. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111711 · Cited by 414 · see citing works

Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.

Hodis, H. N., Mack, W. J., Azen, S. P., Alaupovic, P., Pogoda, J. M., LaBree, L., Hemphill, L., Kramsch, D. M., & Blankenhorn, D. H. (1994) · Circulation · doi:10.1161/01.cir.90.1.42 · Cited by 321 · see citing works

Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.

Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319 · see citing works

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.

Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 283 · see citing works

Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus

Syvänne, M., & Taskinen, M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)90024-6 · Cited by 268 · see citing works

The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.

Weisgraber, K. H., Innerarity, T. L., Harder, K. J., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44181-0 · Cited by 220 · see citing works

Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Cabezas, M. C., de Bruin, T. W. A., de Valk, H. W., Shoulders, C. C., Jansen, H., & Erkelens, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116544 · Cited by 200 · see citing works

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Ebara, T., Ramakrishnan, R., Steiner, G. A., & Shachter, N. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119456 · Cited by 191 · see citing works

Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

Chen, M., Breslow, J. L., Li, W., & Leff, T. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39938-7 · Cited by 184 · see citing works

Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III.

Wj, M., Gesquière, J. C., Bass, H. B., Tartar, A. L., Fruchart, J., & Wang, C. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41415-4 · Cited by 173 · see citing works

Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease

GENESTJR, J., Bard, J., Fruchart, J., Ordovás, J. M., WILSON, P., & Schaefer, E. J. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90109-g · Cited by 122 · see citing works

Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde

Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114 · see citing works

Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.

Aalto‐Setälä, K., Weinstock, P. H., Bisgaier, C. L., Wu, L., Smith, J. D., & Breslow, J. L. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39123-9 · Cited by 114 · see citing works

Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.

Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113 · see citing works

Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis.

Vergès, B. L. (1999) · PubMed · Cited by 108 · see citing works

Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics

BRIONES, E. R., Mao, S. J. T., Palumbo, P. J., O’Fallon, W. M., CHENOWETH, W. L., & Kottke, B. A. (1984) · Metabolism · doi:10.1016/0026-0495(84)90160-4 · Cited by 107 · see citing works

Effect of Insulin Therapy on Metabolic Fate of Apolipoprotein B–Containing Lipoproteins in NIDDM

Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diab.39.9.1017 · Cited by 103 · see citing works

Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes

Gervaise, N., Garrigue, M. A., Lasfargues, G., & Lecomte, P. (2000) · Diabetologia · doi:10.1007/s001250051366 · Cited by 82 · see citing works

Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles

Brousseau, T., Barthelemy-Clavey, V., Bard, J., & Fruchart, J. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.6.960 · Cited by 80 · see citing works

Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition

Pietzsch, J., Subat, S., Nitzsche, S., et al. (1995) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(94)00171-t · Cited by 76 · see citing works

Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia

Campos, H., Perlov, D., Khoo, C., & Sacks, F. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31574-1 · Cited by 73 · see citing works

Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells.

Agnani, G., Bard, J., Candelier, L., Delattre, S., Fruchart, J., & Barthelemy-Clavey, V. (1991) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.11.4.1021 · Cited by 71 · see citing works

Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat

Elam, M. B., Wilcox, H. G., Cagen, L. M., Deng, X., Raghow, R., Kumar, P., Heimberg, M., & Russell, J. C. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31533-9 · Cited by 62 · see citing works

Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E

Chivot, L., Mainard, F., Bigot‐Corbel, E., Bard, J., Auget, J.-L., Madec, Y., & Fruchart, J. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90042-h · Cited by 60 · see citing works

Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat.

Vance, J. E., & Russell, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42620-3 · Cited by 57 · see citing works

Mitogen-activated Protein Kinase Regulates Transcription of the ApoCIII Gene

Reddy, S. L., Yang, W., Taylor, D. G., Shen, X.-Q., Oxender, D. L., Kust, G. A., & Leff, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.33050 · Cited by 49 · see citing works

Very-Low-Density Lipoprotein Triglyceride Metabolism in Non-insulin-dependent Diabetes Mellitus: Relationship to Plasma Insulin and Free Fatty Acids

Howard, B. V., Reitman, J. S., Vasquez, B., & Zech, L. A. (1983) · Diabetes · doi:10.2337/diab.32.3.271 · Cited by 48 · see citing works

Hyperinsulinemia and Triglyceride-Rich Lipoproteins

Steiner, G. A., & Lewis, G. F. (1996) · Diabetes · doi:10.2337/diab.45.3.s24 · Cited by 45 · see citing works

Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels.

Sacks, F., Rouleau, J. L., Moyé, L. A., Pfeffer, M., Warnica, J., Arnold, J., Nash, D., Brown, L., Sestier, F., Rutherford, J. D., et al. (1995) · American Journal of Cardiology · doi:10.1016/s0002-9149(99)80631-6 · Cited by 40 · see citing works

Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM

Taskinen, M., Packard, C. J., & Shepherd, J. (1990) · Diabetes · doi:10.2337/diabetes.39.9.1017 · Cited by 40 · see citing works

Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content

Khoo, C., Campos, H., Judge, H., & Sacks, F. M. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33358-7 · Cited by 37 · see citing works

Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report

Syvänne, M., Rossened, M., Labeur, C., Hilden, H., & Taskinen, M. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90004-3 · Cited by 28 · see citing works

Very-low-density lipoprotein triglyceride metabolism in non-insulin-dependent diabetes mellitus. Relationship to plasma insulin and free fatty acids

Howard, B. V., Reitman, J. S., Vasquez, B., et al. (1983) · Diabetes · doi:10.2337/diabetes.32.3.271 · Cited by 18 · see citing works

Quantification of Human Plasma Apolipoproteins C-I, C-II, and C-III by Radioimmunoassays

BREN, N. D., Rastogi, A., & Kottke, B. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60601-6 · Cited by 17 · see citing works

Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides or triglyceride-rich lipoproteins in humans

Dallongeville, J., Meirhaeghe, A., Cottel, D., et al. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801658 · Cited by 15 · see citing works

Apo C subclasses from non-insulin-dependent diabetic patients - a quantitative comparison with control subjects

VENKATESAN, S., Imrie, H., READ, S., et al. (1995) · Biochemical Society Transactions · doi:10.1042/bst023278s · Cited by 13 · see citing works

Composition of very-low-density lipoproteins in non-insulin-dependent diabetes mellitus.

Ishibashi, S., Yamada, N., Shimano, H., Takaku, F., Akanuma, Y., & Murase, T. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.5.808 · Cited by 12 · see citing works

Abnormal composition of apoproteins C-I, C-II, and C-III in plasma and very-low-density lipoproteins of non-insulin-dependent diabetic Chinese.

Pan, X.-D., Cheung, M. C., Walden, C. E., et al. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.10.1914 · Cited by 9 · see citing works

Lipoprotein Lipids and Apolipoproteins (AI, AII, B, CII, CIII) in Type 1 and Type 2 Diabetes Mellitus in Young Kuwaiti Women

Al‐Muhtaseb, N., Al‐Yusef, A. R., & Bajaj, J. S. (1991) · Diabetic Medicine · doi:10.1111/j.1464-5491.1991.tb01692.x · Cited by 6 · see citing works

Apolipoprotein levels in non-insulin-dependent diabetes mellitus with clinical macroangiopathy.

Ikeda, T., Ohtani, I., Fujiyama, K., et al. (1991) · PubMed · Cited by 4 · see citing works

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · see citing works

Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling

Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337 · see citing works

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196 · see citing works

Postprandial hypertriglyceridemia as a coronary risk factor

Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182 · see citing works

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170 · see citing works

LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients

Lee, S.-J., Campos, H., Moye, L. A., & Sacks, F. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000066131.01313.eb · Cited by 170 · see citing works

Apolipoprotein CIII links dyslipidemia with atherosclerosis

Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98 · see citing works

Potential Effect of an Apoprotein B‐based Algorithm on Management of New Patients with Hypertriglyceridemia Referred to a Specialty Lipid Clinic

Brook, R. D., Doshi, H. H., Bard, R. L., et al. (2009) · Clinical Cardiology · doi:10.1002/clc.20399 · Cited by 1 · see citing works

Metabolism of lipoproteins containing apolipoprotein B-100 in blood plasma of rabbits: heterogeneity related to the presence of apolipoprotein E.

Yamada, N., Shames, D. M., Stoudemire, J. B., et al. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3479 · Cited by 107 · see citing works

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

Reyes‐Soffer, G., Moon, B. C., Hernández‐Ono, A., Dionizovik-Dimanovski, M., Jimenez, J., Obunike, J. C., Thomas, T. A., Ngai, C. I., Fontanez, N., Donovan, D. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2195 · Cited by 33 · see citing works

Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice

Maugeais, C., Tietge, U. J. F., Tsukamoto, K., et al. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32001-0 · Cited by 67 · see citing works

Simultaneous measurement of apolipoprotein B turnover in very-low- and low-density lipoproteins in familial hypercholesterolaemia

Soutar, A. K., Myant, N. B., & Thompson, G. R. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90174-5 · Cited by 154 · see citing works